The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: Focus on therapeutic implications

American Journal of Cardiovascular Drugs

Volumn 11, Issue 3, 2011, Pages 145-152

  Farnier, Michel ^a  

^a Point Médical ^*  (France)

Author keywords

Hyperlipidaemia; LDL receptor modulators; PCSK9 protein inhibitors

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; ATORVASTATIN; BERBERINE; CHENODEOXYCHOLIC ACID; ENZYME ANTIBODY; EZETIMIBE; FARNESOID X RECEPTOR; FENOFIBRATE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KEXIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; REGN 727; SERINE PROTEINASE INHIBITOR; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; SUBTILISIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; AFRICAN AMERICAN; AMINO TERMINAL SEQUENCE; ARTICLE; ATHEROSCLEROSIS; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERANCE; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; GAIN OF FUNCTION MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEPATITIS C VIRUS; HETEROZYGOTE; HIGH RISK PATIENT; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPOCHOLESTEROLEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIVER FUNCTION; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET DELTA CELL; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; RACE DIFFERENCE; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG DELIVERY SYSTEMS; HUMANS; HYPERLIPIDEMIAS; MICE; MUTATION; SERINE ENDOPEPTIDASES;

EID: 79957793377     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11590330-000000000-00000     Document Type: Article

References (77)

1. Baigent C, Keech A, Kearney PM, et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005 Oct; 366: 1267-78
2. Grundy SM, Cleeman JI, Merz CNB, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004 Jul; 110 (2): 227-39 (Pubitemid 38924592)
3. Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007 Oct; 28 (19): 2375-414
4. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007 Feb; 32 (2): 71-7 (Pubitemid 46199197)
5. Costet P, Krempf M, Cariou B. PCSK9 and LDL cholesterol: unravelling the target to design the bullet. Trends Biochem Sci 2008 Sep; 33 (9): 426-34
6. Davignon J, DubucG, Seidah NG. The influence of PSCK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep 2010 Sep; 12 (5): 308-15
7. Mousavi SA, Berge KE, Leren TP. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostatis. J Intern Med 2009 Dec; 266 (6): 507-19
8. Abifadel M, Varret M, Rabè s J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics 2003 Jun; 34 (2): 154-6 (Pubitemid 36666925)
9. Seidah NG. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets 2009 Jan; 13 (1): 19-28
10. Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007 Jun; 282 (25): 18602-12 (Pubitemid 47100234)
11. Poirier S, Mayer G, Poupon V, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem 2009 Oct; 284 (42): 28856-64
12. Li J, Tumanut C, Gavignan JA, et al. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J 2007 Sep; 406 (2): 203-7 (Pubitemid 47310950)
13. McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 2007 Jul; 282 (29): 20799-803 (Pubitemid 47099894)
14. Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004 Mar; 114 (4): 349-53 (Pubitemid 38324948)
15. Allard D, Amsellem S, Abifadel M, et al. Novel mutations of the PSCK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.Hum Mutat 2005 Nov; 26 (5): 497
16. Bourbon M, Alves AC, Medeiros AM, et al., on behalf of the investigators of the Portuguese FH Study. Familial hypercholesterolemia in Portugal. Atherosclerosis 2008 Feb; 196 (2): 633-42
17. Cameron J, Holla OL, Laerdahl JK, et al. Characterization of novel mutations in the catalytic domain of the PCSK9 gene. J Intern Med 2008 Apr; 263 (4): 420-31 (Pubitemid 351342682)
18. Homer VM, Marais AD, Charlton F, et al. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis 2008 Feb; 196 (2): 659-66
19. Noguchi T, Katsuda S, Kawashiri M-A, et al. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis 2010 May; 210 (1): 166-72
20. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nature Genetics 2005 Feb; 37 (2): 161-5
21. Cohen JC, Boerwinckle E, Mosley TH, et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl JMed 2006 Mar; 354 (12): 1264-72
22. Abifadel M, Rabè s JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin/kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat 2009 Apr; 30 (4): 520-9
23. Huang C-C, Fornage M, Llyod-Jones DM, et al. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels. The Coronary Artery Risk Development In young Adults study. Circ Cardiovasc Genet 2009 Aug; 2 (4): 354-61
24. ScarteziniM, Hubbart C, Whittall RA, et al. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy UK men. Clin Science 2007 Dec; 113 (11): 435-41 (Pubitemid 350221385)
25. Miyake Y, Kimura R, Kokubo Y, et al. Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis 2008 Jan; 196 (1): 29-36
26. Hooper AJ, Marais AD, Tanyanyiwa DM, et al. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007 Aug; 193 (2): 445-8 (Pubitemid 47058112)
27. Fasano T, Cefalù AB, Di Leo E, et al. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol 2007 Mar; 27 (3): 677-81
28. Benn M, Nordestgaard BG, Grande P, et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010 Jun; 55 (25): 2833-42
29. Guella I, Asselta R, Ardissino D, et al. Effects of PSCK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population. J Lipid Res 2010 Nov; 51 (11): 3342-9
30. Polisecki E, Peter I, Roberston M, et al. Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis 2008 Sep; 200 (1): 95-101
31. Hallman DM, Srinivasan SR, ChenW, et al. Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from the Bogalusa Heart Study)Am J Cardiol 2007 Jul; 100 (1): 69-72 (Pubitemid 46961903)
32. Herbert B, Patel D, Waddington SN, et al. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler Thromb Vasc Biol 2010 Jul; 30 (7): 1333-9
33. Jeong HJ, Lee HS, Kim KS, et al. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res 2008 Feb; 49 (2): 399-409
34. Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase- 1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004 Aug; 24 (8): 1454-9 (Pubitemid 39050440)
35. Costet P, Cariou B, Lambert G, et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006 Mar; 281 (10): 6211-8 (Pubitemid 43847551)
36. Berge KE, Ose L, Leren TP. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol 2006 May; 26 (5): 1094-100 (Pubitemid 43732117)
37. Browning JD, Horton JD. Fasting reduces plasma proprotein convertase, subtilisin/ kexin type 9 and cholesterol biosynthesis in humans. J Lipid Res 2010 Nov; 51 (11): 3359-63
38. Langhi C, Le May C, Kourimate S, et al. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett 2008Mar; 582 (6): 949-55
39. Cameron J, Ranheim T, Kulseth MA, et al. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 2008 Dec; 201 (2): 266-73
40. Lambert G, Jarnoux AL, Pineau T, et al. Fasting induces hyperlipidemia in mice overexpressing PCSK9: lack of modulation of VLDL hepatic output by the LDLr. Endocrinology 2006 Oct; 147 (10): 4985-95
41. Kourimate S, Le MC, Langhi C, et al. Dual mechanisms for the fibratemediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem 2008 Apr; 283 (15): 9666-73
42. Mayne J, Dewpura T, Raymond A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008 Jun; 7: 22
43. Troutt JS, Alborn WE, Cao G, et al. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res 2010 Feb; 51 (2): 345-51
44. Lambert G, Ancellin N, Charlton F, et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008 Jun; 54 (6): 1038-45 (Pubitemid 351793411)
45. Costet P, Hoffmann MM, Cariou B, et al. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 2010 Sept; 212 (1): 246-51
46. Alborn WE, CaoG,Careskey HE, et al. Serumproprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol. Clin Chem 2007 Oct; 53 (10): 1814-9 (Pubitemid 47509675)
47. Davignon J, Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc 2009; 120: 163-73
48. Dubuc G, Tremblay M, Paré G, et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 2010 Jan; 51 (1): 140-9
49. Lakoski SG, Lagace TA, Cohen JC, et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009 Jul; 94 (7): 2537-43
50. Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/ kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 2008 Aug; 48 (2): 646-54
51. Mayne J, Raymond A, Chaplin A, et al. Plasma PCSK9 levels correlate with cholesterol in men but not in women. Biochem Biophys Res Commun 2007 Sep; 361 (2): 451-6 (Pubitemid 47193117)
52. Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008 Feb; 49 (2): 394-8 (Pubitemid 351213624)
53. Chan DC, Lambert G, Barrett PHB, et al. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism. Clin Chem 2009 Nov; 55 (11): 2049-52
54. Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010 Sep; 51 (9): 2714-21
55. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006 Aug; 48 (3): 438-45 (Pubitemid 44109954)
56. O'Keefe JH, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004 Jun; 43 (11): 2142-6 (Pubitemid 38686815)
57. Steinberg D, Glass CK, Witztum JL. Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation 2008 Mar; 118 (12): 672-7
58. Waters DD, Brotons C, Chiang CW, et al., Lipid Treatment Assessment Project 2 Investigators. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 2009 Jul; 120 (1): 28-34
59. Peters BJ, Klungel OH, de Boer A, et al. Genetic determinants of response to statins. Expert Rev Cardiovasc Ther 2009 Aug; 7 (8): 977-83
60. Thompson JF, Hyde CL, Wood LS, et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet 2009 Apr; 2 (2): 173-81
61. Chien K-L, Wang K-C, Chen Y-C, et al. Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins. Pharmacogenomics 2010 Mar; 11 (3): 309-17
62. Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA 2005 Apr; 102 (15): 5374-9 (Pubitemid 40530265)
63. Hedrick JA. Targeting PCSK9 for the treatment of hypercholesterolemia. Curr Opin Invest Drugs 2009 Sep; 10 (9): 938-46
64. Abifadel M, Pakradouni J, Collin M, et al. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opin Ther Pat 2010 Nov; 20 (11): 1547-71
65. Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007 Apr; 48 (4): 763-7 (Pubitemid 46557881)
66. Franck-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci 2008 Aug; 105 (33): 11915-20
67. Gupta N, Fisker N, Asselin MC, et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One 2010 May; 5 (5): e10682
68. Chan JCY, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci 2009 Jun; 106 (24); 9820-5
69. Ni YG, Condra JH, Orsatti L, et al. A proprotein convertase subtilisin/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem 2010 Apr; 285 (17): 12882-91
70. Palmer-Smith H, Basak A. Regulatory effects of peptides from the pro and catalytic domains of proprotein convertase subtilisin/kexin 9 (PCSK9) on low-density lipoprotein receptor (LDL-R)Curr Med Chem 2010; 17 (20): 2168-82
71. Stein E, Stender S, Mata P, et al., Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004 Sep; 148 (3): 447-55 (Pubitemid 39265117)
72. Stein EA, Ose L, Retterstol K, et al. Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. J Clin Lipidol 2007 Aug; 1 (4): 280-6 (Pubitemid 47364514)
73. Langhi C, Le May C, Gmyr V, et al. PCSK9 is expressed in pancreatic deltacells and does not alter insulin secretion. Biochem Biophys Res Commun 2009 Dec; 390 (4): 1288-93
74. Mbikay M, Sirois F, Mayne J, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett 2010 Feb; 584 (4): 701-6
75. Regeneron Pharmaceuticals, Inc. 2010 PR Newswire [online]. Available from: http://www.regeneron.com//releasedetail.cfm?ReleaseID=493192 [Accessed 2011 May 11]
76. Burlone ME, Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J Gen Virol 2009 May; 90 (Pt5): 1055-70
77. Zhao Z, Tuakli-Wosornu T, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006 Sep; 79 (3): 514-23 (Pubitemid 44384260)